EP300 and acute myeloid leukemia: Current open clinical trials include CCS1477 that blocks the action of p300 and cyclic-AMP response element binding protein, and venetoclax and low dose cytarabine with intensive chemotherapy for NPMmut AML patients over 60 years of age.